{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disease&page=2",
    "query": {
      "condition": "Dermatologic Disease",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disease&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T02:55:21.881Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04739761",
      "title": "A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 506,
      "start_date": "2021-06-22",
      "completion_date": "2027-05-26",
      "has_results": true,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-06-11T02:55:21.881Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Durham, North Carolina",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04739761"
    },
    {
      "nct_id": "NCT06864026",
      "title": "A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Psoriatic Arthritis",
        "Overweight or Obesity"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2025-03-06",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-06-11T02:55:21.881Z",
      "location_count": 53,
      "location_summary": "Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 48 more",
      "locations": [
        {
          "city": "Avondale",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06864026"
    },
    {
      "nct_id": "NCT04602117",
      "title": "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "HER2 Low",
        "SYD-985",
        "SYD985",
        "Vic-trastuzumab Duocarmazine",
        "Metastatic Cancer",
        "Metastatic Breast Cancer",
        "Metastatic Gastrointestinal Carcinoid Tumor",
        "Metastatic",
        "HER2 Low Breast Cancer",
        "GastroEsophageal Cancer",
        "Gastroesophageal Adenocarcinoma",
        "Endometrium Tumor",
        "Ovarian Cancer",
        "Ovarian Carcinoma",
        "HER2-positive Gastric Cancer",
        "HER2-positive Metastatic Breast Cancer",
        "HER2 Mutation-Related Tumors",
        "HER-2 Protein Overexpression",
        "HER2 Low HR Positive",
        "HR Positive",
        "Hormone Receptor-positive Breast Cancer",
        "Estrogen Receptor Positive Tumor",
        "Progesterone Receptor-positive Breast Cancer",
        "Triple Negative Breast Cancer",
        "Hormone Receptor Negative Breast Carcinoma",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Vic-trastuzumab duocarmazine (SYD985) + paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QuantumLeap Healthcare Collaborative",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-07-28",
      "completion_date": "2021-11-17",
      "has_results": false,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-06-11T02:55:21.881Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04602117"
    },
    {
      "nct_id": "NCT07116174",
      "title": "A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Chronic Non-healing DFUs",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetic Foot Ulcer (DFU)"
      ],
      "interventions": [
        {
          "name": "Xcell Amnio Matrix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard of Care (SOC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "New Horizon Medical Solutions",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 135,
      "start_date": "2025-08-15",
      "completion_date": "2026-08-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-06-11T02:55:21.881Z",
      "location_count": 3,
      "location_summary": "Fresno, California • San Diego, California • Dallas, Texas",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07116174"
    },
    {
      "nct_id": "NCT05126290",
      "title": "CTNNA1 Familial Expansion Study",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer Gene Mutation",
        "Gastric Cancer",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Collection of personal and family history from CAFÉ Study participants",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2021-03-16",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-06-11T02:55:21.881Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05126290"
    },
    {
      "nct_id": "NCT04383210",
      "title": "Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Solid Tumor",
        "Metastatic Solid Tumor",
        "Pancreatic Cancer",
        "Lung Cancer",
        "Head and Neck Cancer",
        "Breast Cancer",
        "Kidney Cancer",
        "Colorectal Cancer",
        "Bladder Cancer",
        "Ovarian Cancer",
        "Sarcoma",
        "Gallbladder Cancer",
        "Bile Duct Cancer",
        "Esophageal Cancer",
        "Uterine Cancer",
        "Cholangiocarcinoma",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Seribantumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elevation Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2020-09-29",
      "completion_date": "2024-02-28",
      "has_results": true,
      "last_update_posted_date": "2025-04-03",
      "last_synced_at": "2026-06-11T02:55:21.881Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04383210"
    },
    {
      "nct_id": "NCT00938223",
      "title": "Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "4-peptide and 12-peptide melanoma vaccines",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Craig L Slingluff, Jr",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 51,
      "start_date": "2000-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-05-02",
      "last_synced_at": "2026-06-11T02:55:21.881Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00938223"
    },
    {
      "nct_id": "NCT00733408",
      "title": "Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Estrogen Receptor-negative Breast Cancer",
        "HER2-negative Breast Cancer",
        "Progesterone Receptor-negative Breast Cancer",
        "Recurrent Breast Cancer",
        "Stage IV Breast Cancer",
        "Triple-negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "paclitaxel albumin-stabilized nanoparticle formulation",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 59,
      "start_date": "2008-04-23",
      "completion_date": "2017-09-28",
      "has_results": true,
      "last_update_posted_date": "2018-12-04",
      "last_synced_at": "2026-06-11T02:55:21.881Z",
      "location_count": 17,
      "location_summary": "Anchorage, Alaska • Yuma, Arizona • Lewiston, Idaho + 12 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Lewiston",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00733408"
    },
    {
      "nct_id": "NCT02934360",
      "title": "TR(ACE) Assay Clinical Specimen Study",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "TR(ACE) Assay Testing",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Biological Dynamics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 450,
      "start_date": "2016-09",
      "completion_date": "2018-04",
      "has_results": false,
      "last_update_posted_date": "2018-01-18",
      "last_synced_at": "2026-06-11T02:55:21.881Z",
      "location_count": 16,
      "location_summary": "Encinitas, California • Oceanside, California • Santa Monica, California + 13 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Winter Haven",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02934360"
    },
    {
      "nct_id": "NCT01082523",
      "title": "\"A Randomized, Controlled, Evaluator-blinded Pilot Study to Evaluate the Effect of Automated Text Message Reminders on Patient Compliance With Topical Medications and Its Efficacy on Skin Disease Control in Adolescents and Adults With Mild to Moderate Acne\"",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acne",
        "Patient Compliance"
      ],
      "interventions": [
        {
          "name": "Text message reminders",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "12 Years to 30 Years"
      },
      "enrollment_count": 40,
      "start_date": "2010-02",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2019-09-17",
      "last_synced_at": "2026-06-11T02:55:21.881Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01082523"
    }
  ]
}